XCUR (Exicure, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by XCUR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Exicure HiTron Inc. | 10%+ Owner | J | — | — |
| 2026-02-19 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2026-01-21 | Exicure HiTron Inc. | 10%+ Owner | Sell | — | — |
| 2026-01-20 | Exicure HiTron Inc. | 10%+ Owner | Sell | — | — |
| 2026-01-08 | Exicure HiTron Inc. | 10%+ Owner | Sell | — | — |
| 2025-12-10 | SANGSANGIN INVESTMENT & SECURITIES CO., LTD. | 10%+ Owner | Sell | — | — |
| 2025-11-19 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2025-08-20 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2025-05-23 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2025-03-26 | HiTron Systems Inc. | 10%+ Owner | Buy | — | — |
| 2025-02-24 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2024-11-26 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2024-09-16 | DGP Co., Ltd. | 10%+ Owner | Buy | — | — |
| 2024-08-21 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2024-05-23 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2024-03-06 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2024-03-04 | DGP Co., Ltd. | 10%+ Owner | Sell | — | — |
| 2023-12-01 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2023-08-18 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2023-06-27 | CBI USA, Inc. | 10%+ Owner | C | — | — |
| 2023-05-25 | Josh Miller | Chief Accounting Officer | F | — | — |
| 2023-03-09 | CBI USA, Inc. | 10%+ Owner | J | — | — |
| 2023-01-04 | Jiyoung Hwang | Director | A | — | — |
| 2022-12-19 | CBI USA, Inc. | 10%+ Owner | Buy | — | — |
| 2022-06-15 | JAMES R SULAT | Director | A | — | — |
| 2022-06-15 | Jeffrey L Cleland | Director | A | — | — |
| 2022-06-15 | ELIZABETH A. GAROFALO | Director | A | — | — |
| 2022-06-15 | Bali Muralidhar | Director | A | — | — |
| 2022-05-20 | Sarah Longoria | Chief HR & Compliance Officer | A | — | — |
| 2022-05-19 | Bali Muralidhar | Director | Buy | — | — |
| 2022-05-18 | Elias D. Papadimas | Chief Financial Officer | A | — | — |
| 2022-05-18 | MATTHIAS SCHROFF | Chief Executive Officer | A | — | — |
| 2021-12-22 | WILLIAM H GATES III | 10%+ Owner | Sell | — | — |
| 2021-11-23 | David A Giljohann | Chief Executive Officer | A | — | — |
| 2021-11-23 | Douglas E. Feltner | Chief Medical Officer | A | — | — |
| 2021-09-08 | Elias D. Papadimas | Chief Accounting Officer | Buy | — | — |
| 2021-06-04 | ANDY SASSINE | Director | A | — | — |
| 2021-06-04 | ELIZABETH A. GAROFALO | Director | A | — | — |
| 2021-06-04 | Bali Muralidhar | Director | A | — | — |
| 2021-06-04 | Timothy P Walbert | Director | A | — | — |
| 2021-06-04 | Jeffrey L Cleland | Director | A | — | — |
| 2021-06-04 | Bosun Hau | Director | A | — | — |
| 2021-06-04 | JAMES R SULAT | Director | A | — | — |
| 2021-05-20 | David A Giljohann | Chief Executive Officer | A | — | — |
| 2021-05-20 | MATTHIAS SCHROFF | Chief Operating Officer | A | — | — |
| 2021-05-20 | Douglas E. Feltner | Chief Medical Officer | A | — | — |
| 2021-05-14 | Brian Bock | Chief Financial Officer | A | — | — |
| 2021-05-04 | MATTHIAS SCHROFF | Chief Operating Officer | A | — | — |
| 2021-04-29 | David A Giljohann | Chief Executive Officer | A | — | — |
| 2021-04-29 | Douglas E. Feltner | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,222,224 | — |
| — | 10%+ Owner | 849,223 | — |
| — | 10%+ Owner | 163,660 | — |
| — | 10%+ Owner | 75,051 | — |
| — | Director | 56,328 | — |
| — | 10%+ Owner | 33,765 | — |
| — | Director | 13,725 | — |
| — | Director | 3,123 | — |
| — | Director | 657 | — |
| — | Chief Accounting Officer | 301 | — |
| — | Chief Executive Officer | 258 | — |
| — | Chief Financial Officer | 122 | — |
| — | Chief Financial Officer | 111 | — |
| — | Chief Medical Officer | 100 | — |
| — | Chief Executive Officer | 50 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XCUR quote page; the site-wide leaderboard is on the insider transactions hub.